# Blue Earth Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blue-earth-diagnostics

- Industry: Healthcare
- Headquarters: Oxford, UK
- Website: www.blueearthdiagnostics.com
- Total disclosed funding: $28M
- Latest round: Series B (Jul 23, 2015)
- Investors on record: 1

## About

Blue Earth Diagnostics Ltd. focuses on developing and commercializing advanced molecular imaging products, particularly for cancer diagnostics, to enhance diagnostic accuracy and treatment monitoring in healthcare settings.Founded in 2014 and headquartered in Oxford, UK, Blue Earth Diagnostics Ltd. specializes in the creation of PET radiopharmaceuticals aimed at improving cancer diagnostics. The company underwent a significant transition when it was acquired by Bracco Imaging S.p.A. in a TRADE SALE valued at GBP 354.3 million, completed in August 2019. David Gauden serves as the CEO of the company. Blue Earth Diagnostics has engaged in 3 deals to date, with the most recent occurring on June 27, 2019, marking a pivotal moment in its corporate trajectory.Blue Earth Diagnostics specializes in the development and commercialization of innovative molecular imaging products, particularly in the field of cancer diagnostics. Their core offerings include a suite of PET radiopharmaceuticals designed to enhance the accuracy of cancer detection and treatment monitoring. These products enable healthcare professionals to visualize cancerous lesions with greater precision, ultimately improving patient outcomes. Blue Earth Diagnostics primarily serves hospitals, imaging centers, and oncology practices across several geographical markets, including the United States and Europe. The company has leveraged its expertise in nuclear medicine to create solutions that not only inform treatment decisions but also drive future therapeutic strategies in oncology.In the most recent fiscal year of 2023, Blue Earth Diagnostics generated revenue of GBP 14,131,687. However, the EBITDA for the same year stood at GBP -78,403,176, indicating operational challenges amid their growth efforts in the healthcare market.Blue Earth Diagnostics aims to expand its product offerings and market reach. The company is focused on launching new PET radiopharmaceuticals designed to improve cancer diagnostics. Specific upcoming product release details and timelines are not disclosed. The recent acquisition by Bracco Imaging S.p.A. is expected to bolster Blue Earth's capabilities in penetrating new markets, particularly in Europe and the United States. The GBP 354.3 million from the TRADE SALE will likely support these development initiatives and enhance distribution capabilities, facilitating broader integration of their products into clinical workflows.

## Funding rounds

- Series B, Jul 23, 2015, $28M — Syncona

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Series B